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Background: Evidence is accumulating that a cannabis withdrawal syndrome is common, of clinical significance,
and has a clear time course. Up till now, very limited data exist on the cannabis withdrawal symptoms in patients
with co-morbid substance use disorders, other than cannabis use and tobacco use.
Methods: Symptoms of withdrawal were assessed through patient self-reports during detoxification in Danish
residential rehabilitation centers. Patients (n = 90) completed booklets three times during their first month at the
treatment centre. Self-reported withdrawal symptoms was rated using the DSM-5 Withdrawal Symptom Check List
with withdrawal symptoms from all classes of substances, with no indication that the described symptoms should
be attributed to withdrawal. Self-reported time since last use of cannabis was used as a predictor of cannabis
withdrawal severity.
Results: With the exception of loss of appetite, time since last use of cannabis was associated with all types of
withdrawal symptoms listed in the DSM-5. Only four of 19 symptoms intended to measure withdrawal from other
substances were related to time since last use of cannabis, including vivid, unpleasant dreams.
Conclusions: The findings yield strong support to the notion of a cannabis withdrawal syndrome, and gives further
evidence for the inclusion of the criterion of vivid, unpleasant dreams. Further, the findings speak against the
significance of demand characteristics in determining the course of the symptoms of cannabis withdrawal.
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The cannabis withdrawal phenomenon has received grow-
ing interest in recent years. Cannabis withdrawal does not
typically cause significant medical or psychiatric problems
as do opioid, alcohol, or benzodiazepine withdrawal [1],
but implications of withdrawal symptoms include the risk
of relapse and the well-being of patients [2].
A withdrawal syndrome is characterized by onset after
cessation of drug use followed by a gradual return to
baseline levels, and reversed by new drug use. Until re-
cently, no official definition of a cannabis withdrawal
was listed in the official diagnostic nomenclatures ICD-
10 and DSM-IV.
With the recent publication of the DSM-5, a cannabis
withdrawal syndrome is now officially recognized with
defined criteria [3]. In the following, we shall review the* Correspondence: mh@crf.au.dk
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distribution, and reproduction in any mediumevidence for these criteria as well as comment on criteria
that are listed as ancillary in the DSM-5.Status of the cannabis withdrawal syndrome
In 1994, Carroll and colleagues found that withdrawal
was rarely endorsed by cannabis users, and Guttman
scaling showed that only the most severely affected can-
nabis dependent patients reported cannabis withdrawal
[4]. However, in the absence of specific criteria, respon-
dents may not have interpreted symptoms that occurred
after cannabis cessation as withdrawal symptoms. Later
research has indeed produced a different picture [2].
Studies have found that the cannabis withdrawal syn-
drome appears to be comparable to the tobacco with-
drawal syndrome [5,6], and is associated with severity of
cannabis problems at follow-up [7,8]. Most symptoms of
cannabis withdrawal increase immediately after cessation
and decline over the next weeks [9-11], see however [12].
Additionally, studies have shown that the symptoms ofCentral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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THC [13-15] and that sleep problems associated with can-
nabis withdrawal can be treated with zolpidem [16].
Specific symptoms of cannabis withdrawal listed in the
proposal for DSM-5
Cannabis withdrawal has been recommended for inclu-
sion in the DSM-5 with the following symptoms: A. Ces-
sation of heavy and prolonged cannabis use; B. 3 or
more of the following developments within several days
after cessation: 1. Irritability; 2. Nervousness; 3. Sleep
difficulty; 4. Decreased appetite; 5. Restlessness; 6. De-
pressed mood; 7. Physical symptoms and discomfort.
In the following, studies that have supported the inclu-
sion of these symptoms are presented.
Irritability. Most studies give strong support to the
relevance of irritability and anger as a common and
significant symptom of cannabis withdrawal e.g.
[7,9,11,17-23]. Irritability and anger may have a later
onset and a longer duration than most other
withdrawal symptoms [11]. Additionally, more severe
expressions of aggression, such as attacking someone
physically, may occur later than milder symptoms of
irritability [20].
Nervousness. Nervousness is also a commonly reported
symptom [7,8,11,17,19-23]. Prospective research has
found that nervousness associated with cannabis
withdrawal is a source of significant distress [9], and
that it gradually declines in severity after cannabis
cessation [10,11]. However, not all studies have
supported the significance of nervousness as a
symptom of cannabis withdrawal e.g. [18].
Sleep difficulty. Sleep difficulty or insomnia is also
frequently reported as a withdrawal symptoms
[7-9,11,17,18,20,21], that decrease with time since
cessation [10,11,18]. However, studies have found some
uncertainty regarding the time course: prospective
studies using self-report measures suggest that sleep
problems decline fairly linearly after cessation of
cannabis use [10,11], whereas a study using
polysomnogram data indicated that sleep quality
declined gradually over 13 days with no reversal [24].
Decreased appetite or weight loss. Decreased appetite or
weight loss has been robustly reported across studies
[9,11,18-23] with a quick onset after cessation, followed
by a relatively quick reversal [11].
Restlessness. Restlessness has generally been supported
as a common and significant symptom of cannabis
withdrawal [7-11,17,20,21] with a slightly later onset
than most symptoms [11].
Depressed mood. Depressed mood is also commonly
reported, although not as often as nervousness or
irritability [7,8,17,19-21,23]. Some prospective studieshave failed to show that it follows a clear withdrawal
pattern [11,18], but other research supports its
inclusion as a valid withdrawal symptom [9].
Physical symptoms. Physical symptoms such as
stomach pain, shakiness/tremors, sweating, fever, chills
or headache have been reported at variable rates, and
generally at lower rates compared with other symptoms
[7,8], e.g. [17,20-23], but some research has supported
most of these symptoms as indications of withdrawal
[9], see however [18].
Other symptoms
The withdrawal symptoms listed in the DSM-5 are not
the only symptoms that have been studied in clinical
and experimental research. Some of these other symp-
toms are likely to be highly correlated with symptoms in
the DSM-5, and have been listed as symptoms that may
also occur [3].
A frequently reported symptom is increased appetite
which is about as common as decreased appetite [19-21],
although Allsop and colleagues have reported that it is not
valid as a withdrawal criterion [9].
One of the most commonly reported withdrawal
symptoms not included in the DSM-5 is vivid unpleasant
dreams, although it appears to be as common as the
symptoms listed for the DSM-5 [8,9,11,17,18], see how-
ever [21]. The time course of these dreams differs from
other symptoms studied with a later onset and a longer
duration [11,20]. Vivid, unpleasant dreams is not easily
subsumed under any of the included symptoms in the
DSM-5, but it is worth noting that strange and unpleas-
ant dreams is listed in the DSM-5 criteria for amphet-
amine and cocaine withdrawal.
Methodological limitations in the existing literature
The literature described above shows a fairly consistent
picture of the cannabis withdrawal symptoms that is
largely in line with the proposal to include cannabis with-
drawal in the DSM-5. However, the literature on cannabis
withdrawal presents some methodological challenges. One
potential limitation is the problem of demand characteris-
tics. In psychology, demand characteristics refer to “the
totality of cues which convey an experimental hypothesis
to the subject” [25]. In this context, giving patients cues
that a given instrument is designed to measure withdrawal
from cannabis may prompt them to respond in ways that
they perceive matches what they believe about withdrawal
in general.
For instance, if patients believe that withdrawal is a
temporary cluster of symptoms that begins after cessa-
tion of drug use, they may be more likely to report
symptoms after cessation of use, and stop reporting
these symptoms after a while. Such cues may range
from having cannabis withdrawal in the heading of the
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many days it has been since the subject last used canna-
bis, to having a cannabis craving scale on the same in-
strument. While previous literature has addressed some
aspects of demand characteristics, e.g. by using filler
items [9], using alternative headings, such as “Behavior
Checklist” [18], or asking participants to fill in other
measures simultaneously with marijuana craving ques-
tionnaires [11], all studies have been open about the
study’s focus on marijuana cessation during the recruit-
ment phase, and it has thus been clear to respondents
that questions they have answered may specifically have
been associated with marijuana. This includes the fact
that participants have been asked to choose a quit date
for marijuana, and that they have been asked if they
used marijuana prior to entering the study.
No study has so far used the seven symptoms listed in
the forthcoming DSM-5 together as the indicator of with-
drawal. Studies have either used some of these symptoms
or included other symptoms such as craving.
Finally, the cannabis withdrawal syndrome has not yet
been studied in poly-substance using patients with the
exception of one small cross-sectional study by Vorspan
and colleagues that indicated that sleep disturbances, but
not other cannabis withdrawal symptoms, were exacer-
bated in patients with co-morbid opioid dependence [26].
Arguably, there are good reasons for the omission of poly-
substance using patient samples when establishing the
validity and time course of the cannabis withdrawal syn-
drome. Other drugs may influence mood, physical dis-
comfort, sleep, appetite and overall wellbeing which may
well mask or exacerbate symptoms associated with canna-
bis withdrawal. However, poly-substance dependent pa-
tients make up a large proportion of patients in substance
abuse treatment. If poly-substance abusing patients ex-
perience clinically significant cannabis withdrawal symp-
toms, psycho-education, behavioral and pharmacological
interventions that target the cannabis withdrawal syn-
drome should be made available to such patients.
Aims of the present study
The present study was part of a larger study of residen-
tial treatment in Denmark, funded by the Ministry of
Social Welfare.
The aim of this study was to assess the recommended
withdrawal symptoms of cannabis in the DSM-5 through
patient self-reports during detoxification in Danish resi-
dential rehabilitation centers measured over 4 weeks of
early treatment.
The goals were:
1. To assess the time course of the DSM-5 cannabis
withdrawal syndrome in relation to time elapsed
since last use of cannabis. We hypothesized that theDSM-5 symptoms would follow a curvilinear time
course from cessation of cannabis use characterized
by an increase in severity immediately after cessation
followed by a decrease. This was conducted by
administering a scale consisting of all the criteria
listed in the DSM-5 for cannabis withdrawal three
times over four weeks of treatment.
2. To assess the time course of each individual
symptom of withdrawal, including symptoms
currently listed for other substances than cannabis,
controlling for use of other drugs.
Patients with poly-substance abuse were ideal for this
purpose. If only cannabis users were included in the
study, this would potentially be a cue that the focus of
the study was cannabis-related.
Methods
Procedures
We used the national residential registration base in
Denmark (DanRIS) to identify residential illicit drug
abuse treatment institutions in Denmark. The treatment
services were then contacted through the management
and introduced to the details of the study, either through
prepared information material, or by a visit from the re-
searchers or other staff affiliated with the project. In
total 18 treatment services agreed to participate, and a
staff member was selected as contact person for the re-
searchers and responsible for collection of data at each
site. The contact person at each site received the three
“booklets” that the patients were to fill out during the
first, second and fourth week after beginning treatment.
The three booklets all had questions on substance use,
medical treatment and experience of withdrawal symp-
toms. To reduce demand characteristics, patients were
not instructed to complete the questionnaire on the day
that they last used cannabis.
Following this, staff members at each site introduced
newly enrolled patients to the study. The introduction in
the first booklet was used to describe that filling out the
study booklets would help understanding what problems
substance users had beside their substance use. There
were no exclusion criteria for participating in the study.
Patients were not required to be cannabis dependent for
inclusion in the study. However, patients that were
deemed too chaotic to fill out the booklets, even when
aided by the staff members, or who did not speak
Danish were not approached.
If the patients agreed to participate, they were asked to
give written consent to participation in the study. Danish
institutional review boards do not assess ethics in clinical
studies except those involving invasive medical procedures
or experimental manipulation of drug treatment. This
study did not involve invasive procedures or manipulation,





1. I am more irritable, angry or
aggressive than usually
85% 0.47
2. I am more nervous or anxious
than usually
84% 0.50
3. I have trouble falling asleep 90% 0.26
4. I have no appetite or I have begun
losing weight
54% 0.21
5. I am restless 97% 0.51
6. I feel depressed 84% 0.53
7. I have abdominal pain, I am sweating,
have the chills, as if I had a fever, or I
have a headache
81% 0.44
8. I feel tired 93%
9. I have vivid unpleasant dreams 82%
10. I sleep a lot 81%
11. My appetite has increased a lot 88%
12. I have become so restless that
people notice
74%
13. Others notice that I have become
slow in my movements and when
I speak
43%
14. I yawn a lot all of the time 88%
15. My heart is racing 56%
16. I have a running nose 66%
17. I am sneezing 74%
18. I feel a pricking sensation on
my skin
51%
19. I have gooseflesh, even when it
isn’t cold
65%
20. I feel ill 63%
21. I have spasms 31%
22. I have sore joints or muscles 74%
23. I have the shakes 43%
24. I have runny eyes 49%
25. I am nauseous 42%
26. I have diarrhoea 31%
Notes: items rated on a Likert scale from 0 (not at all) to 3 (severely). Item 1–7
are intended to measure DSM-5 cannabis withdrawal symptoms. Items 8–26
are intended to measure other types of symptoms, and were included in this
study as distracters.
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consent stated that refusal to participate would not influ-
ence the treatment that the patients were receiving at
present. Thus, we can think of no way in which the
present study can be greatly harmful to the participants or
in any way violate the Declaration of Helsinki.
Instruments
Addiction Severity Index (ASI)
All three booklets contained the drug and alcohol sec-
tion from the Addiction Severity Index [27], and patients
answered how many days had elapsed since the last time
they used each substance listed. We estimated the test-
retest reliability of this question by using patients who
completed the questionnaire at least two times, and in-
cluded only patients who had used cannabis in the past
30 days prior to their completion of the week one book-
let. At the second assessment we subtracted the time
elapsed between the two booklets from the time since
last cannabis use for each individual. If the answer was
perfectly reliable, the values would become identical (e.g.,
if a person completed the first booklet two days after last
cannabis use and the second booklet 7 days later, the
expected value would be 9). The test retest correlation of
time since last cannabis was found to be acceptable
(coefficient of concordance = 0.67, 95% CI = 0.51 to 0.82,
Pearson r = 0.69, p < 0.001, n = 48).
Pharmacological treatment
Since there was no standard instrument for collecting
data on type of medical treatment, a questionnaire was
designed for this study to collect data on what types of
medical treatment the patient received at the treatment
service, including average dose of each type of medicine
and number of days since last medicine intake. This
questionnaire was also included in all three booklets.
The DSM-5 withdrawal symptom check list
All items were worded to reflect the withdrawal items in
the DSM-5, based on the then-available criteria on the
DSM-5 webpage. The symptom checklist on withdrawal
symptoms contained 26 items. The instruction stated:
“Right now I experience….”, followed by a list of symp-
toms worded after the DSM-5 criteria for withdrawal
symptoms from cannabis, cocaine, amphetamine, opi-
oids, tranquilizers and alcohol. Items such as hallucina-
tions or seizures that should not occur while patients
were in treatment were not included, since moderate
withdrawal symptoms from alcohol or benzodiazepines
always lead to pharmacological treatment in Denmark.
Each of the 26 items was rated on a four point Likert
scale from “Not at all” to “Severely”. No mention was
made in the questionnaire that the items were intended
to measure withdrawal, or that patients should considerthe time elapsed since they quit using drugs or taking
medication. The items are shown in Table 1, along with
item-total correlations for the cannabis withdrawal items
at week one and the percent ever endorsing the symp-
tom. Table 1 includes only individuals who used canna-
bis in the past 30 days before treatment and completed
more than one booklet.
The reliabilities for the cannabis items using only
respondents who reported using cannabis was 0.71 at
Table 2 Comparison of the study sample and other




N 90 2313 Pearson χ2
Female gender 21% 26% 1.01
Mean SD Mean SD Cohen’s d
Age 29.0 7.4 31.0 8.7 −0.23
ASI composite
scores
N = 621 N = 2096
Drug 0.43 0.20 0.42 0.19 0.05
Alcohol 0.30 0.34 0.23 0.31 0.23
Legal 0.25 0.24 0.22 0.25 0.12
Employment 0.20 0.29 0.12 0.25 *0.32
Financial support 0.86 0.32 0.87 0.29 −0.03
Family 0.36 0.31 0.30 0.30 0.20
Social 0.24 0.27 0.23 0.27 0.04
Psychiatric 0.43 0.28 0.47 0.26 −0.15
Medical 0.36 0.37 0.36 0.38 0.00
Notes: * p < 0.05.
1Of the 90 patients, 28 had not completed the Addiction Severity Index during
their treatment.
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lysis of all respondents who completed the checklist at
week 1 showed that a one factor solution was superior
to a two factor solution using parallel analysis as well as
the Hull Method based on root mean square error of ap-
proximation. The results remained the same, whether
polychoric or Pearson correlation coefficients were used
to assess the factor structure.
Analyses
To assess the time course of symptoms, fixed effects re-
gression was used to test the effects of time elapsed
since last cannabis use, controlling for time since last
use of stimulants (cocaine or amphetamine), opioids
(methadone, heroin or other opioids), and tranquilizers
(alcohol or benzodiazepines). For cannabis, we analyzed
both linear and quadratic effects of time since last use.
The substances were collapsed into classes according to
the types of withdrawal symptoms described in the
DSM-5 [28]. The fixed effects model controls for all
stable characteristics of individuals, thus, effects of co-
variates should be interpreted as within-subject effects.
Missing data for cannabis withdrawal items were
substituted by the respondents’ mean score on all com-
pleted cannabis withdrawal items during the same as-
sessment when calculating the full cannabis withdrawal
scale. When assessing the time course of individual
symptoms, observations with missing data were omitted
from the analysis. Observations with missing data on
time since last use of cannabis or any other substance
were omitted from analyses.
To illustrate the time course and identify peak time
for each symptom, locally weighted regression analysis
was carried out for the full scale and for each criterion
on time elapsed since last use of cannabis.
Results
Participants
A total of 90 patients were included from 18 residential
rehabilitation centers. Participants were 20% women and
80% men, and the mean age was 29.0 (standard deviation
(SD) =7.4). We compared the sample to the general popu-
lation of patients in residential treatment in the DanRIS
database [29], which contains the 30-day questions from
the ASI. The results are shown in Table 2. We found one
statistically significant difference: patients in the study
sample scored higher on concerns about employment.
Cannabis was the most commonly used drug in the
past 30 days, reported by 74%, followed by stimulants
(45%), opioids (42%), benzodiazepines (40%), and drink-
ing 5 or more units of alcohol per day on any day (35%).
The mean number of different substances reported was
4.2 (SD = 3.2). Eleven people used only cannabis in the
past 30 days, and no other illicit drugs, and did notdrink more than 5 drinks containing alcohol on any day.
Patients who did not use cannabis in the past 30 days
were excluded from the analyses. Additionally, patients
who did not complete more than one booklet were ex-
cluded from the analyses.
In all 67 patients completed on average 2.6 booklets
and had on average smoked cannabis 14.4 days prior when
completing the first booklet (median = 9 days, SD = 11.3).
Six patients (7%) had smoked cannabis the day before
completing the first booklet.
Of the patients who could be included in the study,
34% reported receiving antipsychotics during treatment,
29% reported receiving antidepressants during treat-
ment, and 14 (21%) reported receiving both.The DSM-5 cannabis withdrawal symptoms
The items used to assess each symptom are summarized
in Table 2 along with the frequency of respondents ever
endorsing the item. Means over the course of the study
are shown in Figure 1. As can be seen from the graphs
in Figure 1, there were some differences from week one
to week two and four. Most symptoms declined slightly
over time in treatment, except irritability, vivid, unpleas-
ant dreams, increased appetite and increased sleep,
sneezing, fatigue and yawning.
Typical serious opiate withdrawal symptoms such as
spasms, diarrhea, nausea and shaking were rated at low
severity. This may be explained by the fact that many of
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Figure 1 Symptom severity for each withdrawal symptom at first assessment, week 2 assessment and week 4 assessment.
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ent assessment waves.
Missing items made up less than 1% of responses for
any item, and missing data were substituted by means
for the full-scale cannabis withdrawal scale.
The results of the fixed effects regression for the over-
all DSM-5 cannabis withdrawal scale are shown in
Table 3. In model 1 (linear model), cannabis symptoms
decreased by 0.13 points per day elapsed since last use
of cannabis. Time since last use of stimulants, opioids,
alcohol or benzodiazepines was not significantly associ-
ated with cannabis withdrawal symptoms. The course of
symptoms is illustrated in Figure 2. Figure 2 is divided
into two, so that assessments conducted in week one are
in the left panel, and assessments conducted in week
two are in the right hand panel. Within each panel, se-
verity of self-reported symptoms is shown as a function
of days since last use of cannabis with locally weighted
regression estimation.
As can be seen, the symptom severity increased from
day 1 to day 10, and dropped gradually after this. For as-
sessments from week two, no patients reported usingcannabis less than seven days ago, so only an almost lin-
ear decline is seen, following roughly the same values as
in the left-hand panel. Thus, within this group, with-
drawal symptoms follow a time course that is deter-
mined by days since last cannabis use, rather than time
of assessment.
Fixed effects for individual symptoms are summarized
in Table 4. For five of seven symptoms there was a sig-
nificant linear decline with days elapsed since cannabis
cessation: nervousness, insomnia, restlessness, depressed
mood, and physical symptoms. For four of seven symp-
toms, there was a significant curvilinear relationship, indi-
cating in all cases but one that symptoms first increased
and then declined: irritability, nervousness, insomnia and
restlessness. For insomnia, there was a significant curvilin-
ear effect, but the effect was based on a linear decline and
a positive quadratic effect, suggesting that with time the
decline became weaker. However, neither the linear nor
the quadratic coefficient was significant, and curvilinearity
was not evident from inspection of the graph. The course
of specific symptoms as assessed with LOWESS is illus-
trated in Figure 3.
Table 3 Fixed effects regression of the Cannabis withdrawal symptoms
Model 1 Model 2
Coef. SE P-value Coef. SE P-value
Days since last cannabis use −0.130 0.035 0.000 0.051 0.053 0.339
Days since last alcohol or benzodiazepine use −0.070 0.044 0.117 −0.031 0.048 0.523
Days since last opioid use 0.051 0.054 0.346 −0.061 0.044 0.175
Days since last CS use −0.037 0.048 0.441 0.076 0.135 0.576
Days since last cannabis use squared Not included −0.006 0.004 0.118
Constant 11.731 1.174 0.000 10.147 1.527 0.000
Rho 0.641 0.000 0.589 0.000
Notes: CS: Central stimulants. Model 1: linear model. Model 2: quadratic model.
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linear decline or a curvilinear function in time elapsed
since last use of cannabis in this study.
Two of the symptoms that originally intended to
measure cannabis withdrawal were associated with other
substances in the analyses: insomnia was positively asso-
ciated with time elapsed since last use of stimulants, and
loss of appetite declined significantly with time elapsed
since last use of opioids.
To compare the findings with regard to time of onset,
we entered the day of peak of symptoms in Table 5 with
the only published study in which the peak of individual
symptoms was reported [11]. Although the results were
not identically, both studies indicated that irritability/
anger and vivid dreams had a later onset than other
symptoms.
The impact of medications
The impact of antipsychotics and antidepressants was
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Figure 2 Symptom severity for overall cannabis withdrawal syndrome
when assessed at week 1. Right-hand panel: when assessed at week 2.this time adding dummy variables representing antipsy-
chotics and antidepressants to the equation, i.e. when
any subject reported receiving a medication at any point
this was added as a covariate to the equation. This ana-
lysis was repeated for each type of medication. In no in-
stance did medications predict severity of any symptom
or the full withdrawal scale or change the results.
Symptoms of withdrawal from other substances
The remaining 19 symptoms (i.e., symptoms of opioid,
alcohol and stimulant withdrawal) listed in the question-
naire were subjected to the same analyses as the full
withdrawal scale. These symptoms were phrased to iden-
tify symptoms of withdrawal from cocaine, amphet-
amine, opioids, alcohol and tranquilizers. One symptom,
vivid unpleasant dreams, showed evidence of a curvilin-
ear association with time elapsed since last use of canna-
bis, and the Lowess graph is shown in Figure 3.
Another symptom, increased appetite (item 11) in-
creased linearly since last use of cannabis. Finally, two0 0 10 20 30
Assessed at week 2
t cannabis use
as a function of time since last cannabis use. Left-hand panel:
Table 4 Fixed effects slopes for individual symptoms
Linear Quadratic
Symptom: Beta SE F-test (1,145) Beta SE F-test (2,144) Additional substances
Irritability/anger Linear 0.001 0.001 0.03 0.089 0.03 *4.53
Squared −0.003 0.001
Nervousness Linear −0.024 0.008 **9.18 0.025 0.030 **6.08
Squared −0.014 0.008
Insomnia Linear −0.036 0.008 ***18.76 −0.042 0.031 ***9.34 Stimulants +
Squared 0.000 0.000
Loss of appetite Linear −0.006 0.006 1.01 −0.029 0.022 1.09 Opioids -
Squared 0.001 0.001
I am restless Linear −0.024 0.008 **9.66 0.009 0.029 **5.54
Squared −0.001 0.001
I feel depressed Linear −0.016 0.007 *5.37 −0.014 0.027 2.67
Squared −0.000 0.001
Physical symptoms Linear −0.015 0.007 *4.73 −0.034 0.027 2.61
Squared 0.001 0.001
Vivid dreams Linear 0.017 0.009 3.35 0.114 0.033 **6.30
Squared −0.003 0.001
All effects controlled for three additional substances (all time-variant variables): Days since last alcohol or benzodiazepine use; Days since last opioid use; Days
since last CS use.
Coefficients in bold are significant at p < 0.01, coefficients in italics are significant at p < 0.05.
F-tests for linear model test that the linear effect of time since last use of cannabis is significant. F-tests for quadratic models test that the combined effect of the
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Figure 3 Symptom severity for cannabis withdrawal symptoms as a function of time since last cannabis use: irritability, anxiousness,
sleeping difficulties, reduced appetite, restlessness, feeling depressed, physical symptom and vivid dreams. X-axis: days since last
cannabis use. Y-axis: severity rating.
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Table 5 Time course descriptions







Loss of appetite 5 2
Restlessness 6 4
Depression 5 Not reported
Physical symptoms 5 21,5
Vivid dreams 11 9
Notes:
1Averaged over 3 items.
2Averaged over 2 items.
Hesse and Thylstrup BMC Psychiatry 2013, 13:258 Page 9 of 11
http://www.biomedcentral.com/1471-244X/13/258items, fatigue (item 8) and yawning (item 14) showed
evidence of a curvilinear relationship to time since last
use of cannabis, with an increase during the first days,
followed by a decline.
Discussion
This is the first study to assess the DSM-5 cannabis
withdrawal syndrome as described in the coming man-
ual. The findings lend support to the new construct, and
support its conceptualization in the DSM-5.
The study also supports that cannabis withdrawal syn-
drome is partly independent of other drug use. Cannabis
withdrawal followed a clear time-course consistent with
other research with a peak in overall severity 10 days
after last use, followed by a gradual decline over the next
20 days e.g. [9]. This finding was evident, even though
we had attempted to reduce demand characteristics by
not informing patients that a focus of the study was on
cannabis withdrawal.
Out of the seven symptoms listed in the DSM-5, five
showed a linear decrease with time since last use of can-
nabis, and four showed evidence of a curvilinear course
of symptoms with increasing symptoms in the early
days, and declining symptoms in the later days. Evidence
of a linear or curvilinear relationship between days since
last cannabis use was found for only four of 19 symp-
toms of withdrawal from other substances. One of these
symptoms, vivid dreams has been shown to be related to
cannabis withdrawal in previous research [9,11,30]. It is
likely that two of the other symptoms, fatigue and yawn-
ing, both may be influenced by patients experiencing in-
somnia or sleeping problems.
The time course of individual self-reported with-
drawal symptoms largely mirrored what was observed
in the study by Budney and colleagues [11]. The imme-
diate symptoms that peaked within the first week after
cessation in both studies included insomnia, loss of ap-
petite, physical symptoms and restlessness. In the laterphase of withdrawal came irritability/anger, and vivid,
unpleasant dreams, with peaks later than a week after
cessation.
One symptom differed between this study and Budney
and colleagues’ study, namely nervousness, which had an
immediate onset in this study, but peaked only after
9 days in Budney and colleagues’ study. This symptom
was not associated with other drugs reported in our
study, so at present we cannot explain this inconsistency.
And on the other hand, visual inspection of Figure 1 in
the study by Kouri and Pope suggests that in their study,
anxiety peaked almost immediately [23].
The criterion of decreased appetite was not signifi-
cantly associated with time since last cannabis use. It
was however associated with time since last use of opi-
ates, but was rated quite mildly in the patient sample as
a whole. In contrast, patients in this study reported
gradually increasing appetite over the whole 30 days
since their last cannabis use.
Overall, this study gave very considerable support to
the DSM-5 construct. The findings also give further sup-
port to the inclusion of the criterion of vivid unpleasant
dreams, not currently included in the definition.
The consistent finding that the time course of symp-
toms varies may be caused by a wide range of under-
lying mechanisms. Some symptoms may occur as soon
as cannabis use ceases and blood-levels of THC and
other active components in cannabis begin to drop.
Other symptoms may not occur until THC is nearly
completely eliminated from the blood stream. For in-
stance, in the study by Kouri and Pope, it appears that
self-reported increased anxiety, increased physical ten-
sion and appetite loss begins immediately after cessa-
tion, but that irritability low mood and other physical
symptoms accelerate somewhat more slowly as THC
levels drop further [23]. Similarly, we found that ner-
vousness increased immediately after cessation, and
that irritability showed an initial increase followed by a
decrease. For low mood, we found conflicting evi-
dence, with low mood declining linearly from cessation
in our study.
It is likely that medications affect the time course of
withdrawal symptoms. However, this study found that
neither antipsychotics nor antidepressants changed the
results of severity of symptoms across time. Some of the
mechanisms may also be psychological factors such as
expectations to sensations after cessation of drug use.
Explaining this variability may yield important informa-
tion for the understanding of the underlying mecha-
nisms in the cannabis withdrawal syndrome.
Another interesting option is to either maintain or
taper patients on THC-based medications [14] or medi-
cations directed at particular symptoms such as sleep
disturbances [16].
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This study had some limitations that must be acknowl-
edged. We were not able to ensure that participants
completed the questionnaires at pre-fixed times since
their last use of cannabis. Instead, we had to rely on self-
reported time since their last cannabis use. Additionally,
we did not assess severity of dependence, a factor that
has been shown to be very important in predicting who
will develop significant withdrawal, more so than fre-
quency of use or amounts [9]. Further, we did not know
the amount of each drug consumed, or the duration of
time that the patients had used various substances. This
could potentially affect the withdrawal symptoms associ-
ated with various substances, and this is a limitation that
needs to be assessed in future studies of withdrawal in
patients with poly-substance use disorders.
A further limitation is that the sample size is not very
large. Interpretations concerning individual symptoms
should be done in light of the existing literature, rather
than based on significance testing, given that this study
included multiple tests.
We were not able to collect baseline data from the pa-
tient sample while patients were still using cannabis or
other drugs and alcohol. In spite of this, the time course
described in both the graphical and statistical analyses of
the data was remarkably similar to the time course in at
least two previous studies where baseline data included
current drug use - one for individual symptoms [11], and
one for the total severity of symptoms [9].
Although we attempted to reduce the probability of
demand characteristics in the symptom withdrawal ques-
tionnaire, patient ratings may be affected by the fact that
it was administered at the same time that the participants
were questioned about their drug cessation status. Also, it
cannot be out ruled that the data collection was affected
by the treatment providers at the treatment institutions.
An additional limitation of the study is that we were not
able to obtain a sample of all patients who were consecu-
tively admitted to treatment. However, a comparison of
our sample with the general patient population in residen-
tial treatment institutions in Denmark in the same period
showed that the patient sample in this study was compar-
able in terms of age, gender composition, types of drug
use and problem severity.
Urine control with our patients was quite sporadic,
but given that the patients were in residential rehabilita-
tion centers, there is a low risk that the patients would
have access to drugs during their stay. We do, however,
acknowledge the potential risk that the treatment pro-
viders that collected the data for this study could have
influenced patient reports on drug use.
A further limitation is that we do not know to which
extent findings concerning different symptoms may have
been associated with other life stressors, including theparticular stress associated with having arrived at a resi-
dential treatment institution and being removed from
friends or family. It is possible that this might create a
temporary increase in stress over the first few days of
treatment, or that patients become increasingly aware of
both physical and psychological symptoms as they move
away from the hassles of the drug using lifestyle. Further
research is needed to disentangle this relationship.
Clinical implications
This study and other studies on cannabis withdrawal
symptoms stress the need for developing interventions that
target symptoms related to cannabis withdrawal. Limited
evidence is available concerning pharmacological treatment
[13,31]. Some clinicians recommend psychoeducation [32],
but we know of no studies of the usefulness of this ap-
proach. Further research is needed to identify efficacious
behavioral or pharmacological interventions.
Conclusion
The findings yield strong support to the notion of a
specific cannabis withdrawal syndrome. With the excep-
tion of loss of appetite, cannabis withdrawal symptoms
in this study were associated with all types of withdrawal
symptoms listed in the DSM-5. Findings in this study
give further evidence for the inclusion of the criterion of
vivid, unpleasant dreams, not listed in the current DSM-
5 proposal, and challenge the significance of demand
characteristics in determining the course of the symp-
toms of cannabis withdrawal.
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